A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

This study is testing a new drug called SCTB14 as a first-line treatment for people with advanced or metastatic non-small cell lung cancer (NSCLC) — a common form of lung cancer that has spread or cannot be removed surgically. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced or metastatic NSCLC that cannot be cured with surgery or radiation - You are in generally good physical condition (able to carry out daily activities) - Your expected survival is at least 3 months - Your lung cancer does not have EGFR or ALK mutations (if non-squamous type) **You may NOT be eligible if...** - You have already received prior chemotherapy or immunotherapy for this stage of lung cancer - Your tumor has EGFR or ALK mutations (specific targeted therapies exist for those) - You are not well enough to participate in a clinical trial Talk to your doctor to see if this trial is right for you.